High-dose alectinib for RET fusion-positive non-small cell lung cancer in the Blood First Assay Screening Trial

High-dose alectinib for RET fusion-positive non-small cell lung cancer in the Blood First Assay Screening Trial

Bibliographic Details
Main Authors:	Rafal Dziadziuszko, Nir Peled, Tony Mok, Solange Peters, Santiago Ponce Aix, Jorge Alatorre-Alexander, Brian D. Vicuna, Margaret Maclennan, Vijay Bhagawati-Prasad, Sarah M. Shagan, Erica Schleifman, Thorsten Ruf, Michael S. Mathisen, Shirish M. Gadgeel
Format:	Article
Language:	English
Published:	Termedia Publishing House 2024-02-01
Series:	Contemporary Oncology
Subjects:	alectinib blood-based assay blood first assay screening trial (bfast) non small cell lung cancer nsclc ret fusion ctdna circulating tumour dna liquid biopsy ngs
Online Access:	https://www.termedia.pl/High-dose-alectinib-for-RET-fusion-positive-non-small-cell-lung-cancer-in-the-Blood-First-Assay-Screening-Trial,3,52369,1,1.html

Similar Items

Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory <i>ALK</i>-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)
by: Satoshi Watanabe, et al.
Published: (2022-12-01)

Symptomatic Bradycardia Due to Alectinib in a Patient with Advanced Stage of NSCLC
by: Ceva Wicaksono Pitoyo, et al.
Published: (2022-04-01)

Case report: Drug-drug interaction between alectinib and apixaban in NSCLC
by: J.L. Gulikers, et al.
Published: (2022-09-01)

Efficacy and Safety of Dose-Escalated Alectinib in Patients With Metastatic ALK-Positive NSCLC and Central Nervous System Relapse on Standard-Dose Alectinib
by: Justin M. Cheung, MD, et al.
Published: (2024-03-01)

Lorlatinib After Alectinib-Induced Pneumonitis: A Case Report
by: James A. Fletcher, M.B.B.S., et al.
Published: (2024-02-01)

Photophysical Exploration of Alectinib and Rilpivirine: Insights from Theory and Experiment
by: Chun Zhang, et al.
Published: (2023-08-01)

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
by: Naoko Imanishi, et al.
Published: (2018-03-01)

Early Development of Ubiquitous Acanthocytosis and Extravascular Hemolysis in Lung Cancer Patients Receiving Alectinib
by: Julia Kunz, et al.
Published: (2022-05-01)

Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China
by: Zihua Zou, et al.
Published: (2022-01-01)

Alectinib and lorlatinib function by modulating EMT-related proteins and MMPs in NSCLC metastasis
by: Xu Feng, et al.
Published: (2021-06-01)

Focus on Alectinib and Competitor Compounds for Second Line Therapy in ALK Rearranged NSCLC
by: Samuel J Klempner, et al.
Published: (2016-11-01)

Spontaneous Bilateral Chylothorax Development During Alectinib Therapy for ALK-Rearranged NSCLC—A Case Report
by: Sunanjay Bajaj, MD, et al.
Published: (2023-12-01)

Precision oncology for RET-related tumors
by: Antonella Verrienti, et al.
Published: (2022-08-01)

Uterine Leiomyosarcoma with FN1-Anaplastic Lymphoma Kinase Fusion Responsive to Alectinib and Lorlatinib
by: Stefano Testa, et al.
Published: (2021-06-01)

Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis
by: Koichi Ando, et al.
Published: (2021-07-01)

Water Sources Derived Bio Retting Effect on Kenaf Fiber Compositions
by: Mohammad Munir Hossain, et al.
Published: (2022-10-01)

Thyroid dysfunction induced by alectinib in a patient with a non-small cell lung cancer
by: L. Plaza-Enriquez, et al.
Published: (2022-06-01)

Alectinib treatment improves photodynamic therapy in cancer cell lines of different origin
by: Bernhard Gillissen, et al.
Published: (2021-08-01)

Development of Alectinib-Suspended SNEDDS for Enhanced Solubility and Dissolution
by: Eun Ji Park, et al.
Published: (2022-08-01)

Clinical case of prolonged use of alectinib in the treatment of ALK-positive NSCLC
by: S. G. Bagrova, et al.
Published: (2019-12-01)

KRAS mutation as a mechanism of resistance to Alectinib in ALK rearranged NSCLC
by: Ullas Batra, et al.
Published: (2021-03-01)

RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation
by: Takuo Hayashi, et al.
Published: (2021-02-01)

Real-world outcomes of chemoimmunotherapy and selective RET inhibitors in Chinese patients with RET fusion-positive non-small cell lung cancer
by: Rui Wan, et al.
Published: (2024-01-01)

High incidence and reversible bradycardia events following alectinib initiation
by: Dongqi Yuan, et al.
Published: (2023-02-01)

Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC
by: Maiken Parm Ulhoi, et al.
Published: (2021-09-01)

BIOINOCULANTS FOR COIR RETTING
by: A. N. Ravindranath, et al.
Published: (1995-06-01)

RET/PTC translocations and clinico-pathological features in human papillary thyroid carcinoma (PTC)
by: Cristina eRomei, et al.
Published: (2012-04-01)

ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature
by: Nobuaki Mamesaya, et al.
Published: (2017-07-01)

RET Receptor Tyrosine Kinase: Role in Neurodegeneration, Obesity, and Cancer
by: Arun Kumar Mahato, et al.
Published: (2020-09-01)

COMPARATIVE ANALYSIS OF BLOOD GROUPING IN HEALTHY BLOOD DONOR USING GEL CARD TECHNIQUE AND TUBE METHOD
by: Muhammad Usman, et al.
Published: (2016-12-01)

Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alectinib
by: Cass G. G. Sunga, et al.
Published: (2023-03-01)

Dramatic response to alectinib in a patient with ALK‐rearranged squamous cell lung cancer
by: Jun Shiihara, et al.
Published: (2021-09-01)

Alectinib-Induced Erythema Multiforme and Successful Rechallenge with Alectinib in a Patient with Anaplastic Lymphoma Kinase-Rearranged Lung Cancer
by: Tatsuo Kimura, et al.
Published: (2016-12-01)

Improved microbial retting and quality jute (Corchorus spp.) fibre production in India – A review
by: B MAJUMDAR, et al.
Published: (2022-12-01)

RET signaling pathway and RET inhibitors in human cancer
by: Angelina T. Regua, et al.
Published: (2022-07-01)

Chinese siblings with hereditary medullary thyroid carcinoma caused by RET mutation: implications for RET oncogene detection
by: Qin Huang, et al.
Published: (2020-05-01)

Case report: Dramatic response to pralsetinib in an elderly patient with advanced RET-fusion positive papillary thyroid carcinoma
by: Margherita Nannini, et al.
Published: (2022-12-01)

AST-487 Inhibits RET Kinase Driven TERT Expression in Bladder Cancer
by: Neeraj Agarwal, et al.
Published: (2022-09-01)

Characteristics of central nervous system progression in non‐small cell lung cancer treated with crizotinib or alectinib
by: Hiroaki Sakamoto, et al.
Published: (2021-12-01)

Case report: Dramatic response to alectinib in a lung adenosquamous carcinoma patient harbouring a novel CPE-ALK fusion
by: Yanyan Qin, et al.
Published: (2022-12-01)